Skip to main content

Table 1 Study characteristics

From: The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review

First author, year of publication Study design Sample size Sample size for RRSO Age at time of studya, mean (range/SD)b BRCA status (%) Menopause status at time of RRSO (%) Age at RRSO surgery, mean(range/SD)b Comparator Quality rating
Challberg, 2011 [33] Cross-sectional survey design 212 212 50(36-77) BRCA1 & BRCA2 (58%) Premenopausal (100%) 41.20 (24-48) Non-exposed and previous users Low
Chapman, 2011 [37] Cross-sectional survey design 51 51 49 (36-54) BRCA1 (63%) & BRCA2 (37%) Premenopausal (47%) & Postmenopausal (53%) 46 (31–68) Non-exposed Low
Eisen, 2008 [21] Matched case control study 472 136 NS BRCA1 (100%) Premenopausal (100%) 42.45 (28 – 52)c Control (no outcome) High
Finch, 2011 [38] Prospective cohort study 114 114 53(42-74) BRCA1 (51%) & BRCA2 (49%) Premenopausal (66%) & Postmenopausal (34%) 47.50 (35-69) Non-exposed, baseline Low
Gabriel, 2008 [28] Retrospective cohort study 73 73 NS BRCA1 (64%) & BRCA2 (38%) Premenopausal (NS) & Postmenopausal (NS) 42 (29.5-59.2) Non-exposed Low
Garcia, 2015 [30] Retrospective chart review 225 225 NS BRCA1 & 2 (100%) Premenopausal (NS) & Postmenopausal (NS) 50 (31-80) Non-exposed Low
Heiniger, 2014 [29] Matched prospective cohort design 233 38 NS BRCA1 & 2 (16.7%) Premenopausal (NS) & Postmenopausal (NS) NS Non-exposed and previous users Low
Johansen, 2016 [36] Retrospective cohort study 1522 294 54(33-83) NSd Premenopausal (NS) & Postmenopausal (NS) 48(31-76) Non-exposed Low
Kotsopoulos, 2016 [31] Matched case control study 864 210 NS BRCA 1 (100%) Premenopausal (NS) & Postmenopausal (NS) 42.75(28-53)c Control (no outcome) Low
Madalinska, 2006 [34] Cross-sectional survey design 450 450 46 ± 6 (range34-59) BRCA1 & 2 (48%) Premenopausal (100%) 43 ± 6 Non-exposed High
Michelsen, 2009 [35] Cross-sectional survey design 1956 326 54.4(8.9) BRCA1 & 2 (20%) Premenopausal (NS) & Postmenopausal (NS) 48 ± 7.8 Non-exposed High
Rebbeck, 2005 [20] Prospective cohort study 462 155 42.7(37-78) BRCA1 (70%) & BRCA2 (30%) Premenopausal (NS) & Postmenopausal (NS) NS Non-exposed High
Tucker, 2016 [32] Cross-sectional survey design 119 119 NS BRCA1 (8.40%) & BRCA2 (11.70%) Premenopausal (43%) & Postmenopausal (57%) 50(33-69) Non-exposed Low
  1. NS Not specified, RRSO Risk-reducing salpingo-oophorectomy
  2. afor RRSO cohort only; bbased on the measure of variance reported in the primary study; caverage age at surgery among cases and controls; dBRCA status is captured in the questionnaire but not reported in paper